SUPPORTING DATA IN YOUR COMFORT ZONE

FUROSCIX BIOAVAILABILITY AND PHARMACODYNAMIC RESPONSE WERE EVALUATED IN AN OPEN-LABEL, CROSSOVER STUDY COMPARING SUBCUTANEOUS FUROSEMIDE VS IV FUROSEMIDE*^1,2

BIOAVAILABILITY OF FUROSCIX WAS DEMONSTRATED AT 99.6%^†1,2

a graph depicting the bioavailability of furoscix over time

FUROSCIX ACHIEVED DIURESIS EQUIVALENT TO IV FUROSEMIDE^†1,2

a graph comparing furoscix diuresis compared to IV furosemide diuresis

Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.

*The design of the infusor used in this study was different from the FUROSCIX On-Body Infusor, but it used the same administration profile.

†90% confidence interval of 94.8-104.8.

See how patients successfully used FUROSCIX at home.

Learn More

References: 1. Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3(1):25-34. Published 2018 Feb 7. doi:10.1016/j.jacbts.2017.10.001. 2. FUROSCIX [prescribing information]. Burlington, MA: scPharmaceuticals Inc.; 2022.

SUPPORTING DATA IN YOUR COMFORT ZONE

FUROSCIX BIOAVAILABILITY AND PHARMACODYNAMIC RESPONSE WERE EVALUATED IN AN OPEN-LABEL, CROSSOVER STUDY COMPARING SUBCUTANEOUS FUROSEMIDE VS IV FUROSEMIDE*1,2

BIOAVAILABILITY OF FUROSCIX WAS DEMONSTRATED AT 99.6%†1,2

FUROSCIX ACHIEVED DIURESIS EQUIVALENT TO IV FUROSEMIDE†1,2

FUROSCIX BIOAVAILABILITY AND PHARMACODYNAMIC RESPONSE WERE EVALUATED IN AN OPEN-LABEL, CROSSOVER STUDY COMPARING SUBCUTANEOUS FUROSEMIDE VS IV FUROSEMIDE*^1,2

BIOAVAILABILITY OF FUROSCIX WAS DEMONSTRATED AT 99.6%^†1,2

FUROSCIX ACHIEVED DIURESIS EQUIVALENT TO IV FUROSEMIDE^†1,2